Abstract. Long non-coding RNAs (lncRNAs) have been proven to serve vital roles in various human diseases. However, their involvement in the development of pleomorphic adenoma (PA) in the salivary gland has yet to be examined. In the present study, microarray analysis of the lncRNA and mRNA expression profiles in pleomorphic adenoma gene 1 (PLAG1) transgenic mice was performed. Next, bioinformatics tools were used to predict the differentially expressed genes associated with PA, including Gene Ontology (GO), Kyoto Encyclopedia of Genes and Genomes (KEGG) pathway enrichment and lncRNA-mRNA co-expression network analyses. Comparison of the transgenic and control mice demonstrated that a total of 9,110 lncRNAs and 7,750 mRNAs were significantly differentially expressed (fold change >2; P<0.05). Subsequently, six lncRNAs were randomly selected for further analysis, and five of these were validated as differentially expressed in PA by quantitative polymerase chain reaction, supporting the methodology employed in the current study. The GO and KEGG enrichment analysis of the differentially expressed mRNAs revealed that these mRNAs were closely associated with a number of processes involved in the development of PA. Furthermore, the lncRNA-mRNA co-expression network indicated that certain lncRNAs may serve vital roles in the pathogenesis of PA by interacting with a number of core genes. Taken together, these results indicated that lncRNAs and mRNAs were differentially expressed in PA tissues obtained from PLAG1 transgenic mice as compared with those from control mice. These differentially expressed lncRNAs may act as novel biomarkers and therapeutic targets for PA.

Introduction

Neoplasms of the salivary glands constitute 2-10% of all head and neck tumors (1,2). Among these, pleomorphic adenoma (PA), also known as ‘mixed tumor’, is one of the most common types of benign neoplasm of the salivary gland (3). PA presents as a slow-growing, painless and multi-nodular tumor that most frequently occurs in the parotid gland and less often in the submandibular gland, while it rarely occurs in the sublingual gland. The standard treatment for PA is extra-capsular excision of the tumor with or without partial excision of the affected gland. However, partial PA may recur or transform into carcinoma ex PA following surgery, which can lead to mortality in these patients (4).

Pleomorphic adenoma gene 1 (PLAG1), located on chromosome 8q12, is best known for its involvement in the development of various human tumors, such as lipoblastoma and hepatoblastoma (5,6). Targeted disruption of PLAG1 may cause fetal growth restriction, and reduce sperm output and motility (7,8). In salivary gland tumors, PLAG1 was initially identified as an oncogene associated with PA (9-11). More recently, it was demonstrated that this gene is also associated with carcinoma ex PA (12,13). In our previous studies, PLAG1 transgenic mice were established, whose submandibular PA resembles the salivary gland PA of humans (14-16).

lncRNAs are a class of regulatory molecules that consist of >200 nucleotides and are not translated into proteins. A variety of lncRNAs have been identified in human and mouse diseases using large-scale analyses of RNA sequence data (17,18). However, the correlation between lncRNAs and salivary gland diseases has not yet been widely studied. The lncRNA LINC00473 is a downstream target and an important mediator of the CRITC1-MAML2 fusion oncoprotein, which represents a promising biomarker.
and therapeutic target for human CRTC1-MAML2-positive mucoepidermoid carcinoma (19). Numerous IncRNA transcripts have been reported to be dysregulated in the labial salivary glands of patients with primary Sjögren's syndrome, which may serve important roles in the pathogenesis of this disease (20). These previous studies have indicated the crucial role of IncRNAs in salivary gland diseases. However, the expression of IncRNAs in PA remains unclear.

To the best of our knowledge, the present study is the first to use an IncRNA microarray to characterize the expression profiles of IncRNAs and mRNAs in the PLAG1 transgenic murine model of PA. The results indicated that dysregulated IncRNAs may serve a vital role in the pathogenesis of PA.

Materials and methods

Animals and sample collection. All animal experiments were approved by the Ethics Committee of the Faculty of Medicine, Shanghai Jiao Tong University (Shanghai, China). The PLAG1 transgenic mice were generated as described in our previous studies (14,15). Briefly, mouse mammary tumor virus-PLAG1 transgenic mice were maintained in C57BL/6 background. A total of three male transgenic mice (age, 12 weeks; weight, 25-30 g) were used as control group. All animals were purchased from The Shanghai Slake Laboratory Animal Co., Ltd (Shanghai, China). All mice were housed in cages under standard conditions at 24°C under a 12-h light/dark cycle with a relative humidity of 55%. All mice had free access to food and water. Submandibular tumors (average diameter, 1.5 cm) from 3-month-old transgenic mice (average diameter, 1.5 cm) from 3-month-old transgenic mice were divided into two groups, the tumor group, including mouse tumor 1 (MT1), MT2 and MT3 and the control group (Con1, Con2 and Con3). These samples were analyzed independently for the expression of IncRNAs and mRNAs. Another six pairs of mouse tumors and control glands were used for subsequent polymerase chain reaction (PCR) detection.

RNA extraction. Total RNA was extracted from the mouse tumors and control glands using TRIzol® reagent (Thermo Fisher Scientific, Inc., Waltham, MA, USA). RNA quantity and quality were measured using a NanoDrop ND-1000 spectrophotometer (Thermo Fisher Scientific, Inc.). RNA integrity was assessed by standard denaturing agarose gel electrophoresis.

Microarray analysis. Arraystar Mouse LncRNA Microarray V3.0 (Arraystar, Inc., Rockville, MD, USA) is designed for the global profiling of mouse IncRNAs and protein-coding transcripts. Following RNA labeling and array hybridization, the microarray was scanned using the Agilent Microarray Scanner (Agilent p/n G2565BA; Agilent Technologies, Inc., Santa Clara, CA, USA). The Agilent Feature Extraction Software was used to extract data and for subsequent data processing. The IncRNA exhibiting a fold-change ≥2 and P<0.05 compared with the control were considered as differentially expressed.

Gene Ontology (GO) and Kyoto Encyclopedia of Genes and Genomes (KEGG) pathway enrichment analysis. GO analysis was conducted to identify the functions of differentially expressed genes, including biological processes, molecular functions and cellular components. Furthermore, the pathways associated with the differentially expressed mRNAs were assessed using KEGG analysis. Significant GO terms and pathways were selected on the basis of FDR<0.05 and false discovery rate of <0.05. The unsupervised hierarchical clustering of the top 20 dysregulated IncRNAs and mRNAs was also performed.

Reverse transcription-quantitative PCR (RT-qPCR) validation. Subsequent to extraction, total RNA was reverse transcribed into cDNA using the PrimeScript RT Master Mix (Takara Biotechnology Co., Ltd., Dalian, China), according to the manufacturer's protocol. A total of four upregulated and two downregulated IncRNAs were selected for PCR validation on the basis of fold change (FC). The qPCR experiment was performed using SYBR Premix Ex Taq II (Takara Biotechnology Co., Ltd.) on the 7500 Sequence Detection system (ABI; Thermo Fisher Scientific, Inc.). The following thermocycling conditions were used: Initial denaturation at 95°C for 10 min, followed by 40 cycles of 95°C for 10 sec and 60°C for 60 sec. GAPDH (mouse) was used as an endogenous control, and relative expression levels of each IncRNA was calculated using the 2-ΔΔCq method. The primer sequences of investigated IncRNAs are listed in Table I.

Construction of the IncRNA and mRNA co-expression network. The aforementioned validated IncRNAs were used to construct a co-expression network to explore specific mRNAs involved in PA tumorigenesis. The Pearson correlation coefficient (PCC) was calculated for correlations between the validated IncRNAs and all the differentially expressed mRNAs. The IncRNAs and mRNAs with an absolute value of Pearson correlation coefficients >0.995 were selected to draw the gene network using the program Cytoscape (version 3.0.1; https://cytoscape.org/).

Statistical analysis. Statistical analyses were performed using SPSS software (version 19.0; IBM Corp., Armonk, NY, USA). For normally distributed data, the differences between two groups were determined using a two-tailed Student's t-test. P<0.05 was considered to indicate a statistically significant difference.

Results

Overview of IncRNA and mRNA expression profiles. To identify the differentially expressed IncRNAs associated with PA tumorigenesis, the present study examined the expression pattern of IncRNAs in three submandibular tumors from PLAG1 transgenic mice and three normal submandibular samples from control wild-type mice. The expression profiles of the IncRNAs and mRNAs are listed in Table II. The present data demonstrated that 25.36% of the IncRNAs (9,110/35,923) and 31.15% of the mRNAs (7,750/24,881) were significantly differentially expressed in the tumor group as compared with those in the control group (FC>2, P<0.05). The unsupervised hierarchical clustering of the top 20 upregulated and downregulated IncRNAs and mRNAs indicated that the expression patterns of the three samples in each group were similar, as indicated by the heat map (Fig. 1).
Differentially expressed lncRNAs in PLAG1 transgenic mice and wild-type mice. Volcano plot filtering was used to identify the differences in the expression of lncRNAs between the PLAG1 transgenic mice and control mice (Fig. 2A). The plot demonstrated that a total of 9,110 lncRNAs (4,521 upregulated and 4,589 downregulated) were significantly differentially expressed. The chromosome distribution of the differentially expressed lncRNAs was then determined. As illustrated in Fig. 2B, chromosome 2 exhibited the highest number of differentially expressed lncRNAs, while chromosome Y exhibited the lowest number. On the basis of different transcriptional forms, the differentially expressed lncRNAs were

Table I. Primer sequences.

| Primer name            | Sequence                                  | Annealing temperature (°C) | Product length (bp) |
|------------------------|-------------------------------------------|----------------------------|---------------------|
| GAPDH (mouse)          | F: 5'-CACTGAGCAAGAGAGGCCCCTAT-3'         | 60                         | 144                 |
|                        | R: 5'-GCAGCGAAGTTATGTATGATT-3'           |                            |                     |
| ENSMUST00000140495     | F: 5'-TCGTGTTGGTTTTATCAAGCAAG-3'         | 60                         | 203                 |
|                        | R: 5'-ATAGGCTCCGACTGTTGTT-3'             |                            |                     |
| ENSMUST00000125649     | F: 5'-CGATGACAAGCTAGAGGACA-3'            | 60                         | 118                 |
|                        | R: 5'-GCCCTCTTGGCTGATCTATTCT-3'          |                            |                     |
| AK006017               | F: 5'-TGACACCGGGGTCTGAGTAT-3'            | 60                         | 210                 |
|                        | R: 5'-CCGTAGGCTGAAATATTCTGCTC-3'         |                            |                     |
| AK146794               | F: 5'-TGGATGTAACAAACTATGTTG-3'           | 60                         | 65                  |
|                        | R: 5'-TGAGGGAATGAGGCAAGAGAAG-3'          |                            |                     |
| ENSMUST00000120145     | F: 5'-AGAAGCTAGTTCTATAGGAAGCAG-3'        | 60                         | 137                 |
|                        | R: 5'-CATAGATGCTCCAGAAAGGAC-3'           |                            |                     |
| AK089826               | F: 5'-GTGTTACAGTATCGCTAAAGGAC-3'         | 60                         | 142                 |
|                        | R: 5'-GGGAAAACATAGTGATAGGAGC-3'          |                            |                     |

Table II. Summary of the results of lncRNA and mRNA profile analyses.

| Probe class | Total, n | Differentially expressed, n (%) | Upregulated, n (%) | Downregulated, n (%) |
|-------------|----------|---------------------------------|--------------------|----------------------|
| lncRNAs     | 35,923   | 9,110 (25.36)                   | 4,521 (12.59)      | 4,589 (12.77)        |
| mRNAs       | 24,881   | 7,750 (31.15)                   | 4,201 (16.88)      | 3,549 (14.26)        |
| Combined    | 60,804   | 16,860 (27.73)                  | 8,722 (14.34)      | 8,138 (13.38)        |

lncRNA, long noncoding RNA.

Figure 1. Heatmap of the differentially expressed (A) lncRNAs and (B) mRNAs. In the heatmap, red represents upregulated lncRNAs or mRNAs, while yellow represents downregulated lncRNAs or mRNAs. lncRNA, long noncoding RNA; MT, mouse tumor; Con, control.
classified into six different subgroups, including bidirectional, exon sense-overlapping, intergenic, intron sense-overlapping, intronic antisense and natural antisense lncRNAs. The majority of the differentially expressed lncRNAs were classified as intergenic and exon sense-overlapping lncRNAs, both in the upregulated and downregulated groups (Fig. 2C and D).

**GO and KEGG pathway analyses of differentially expressed mRNAs.** GO analysis was conducted to determine the enrichment of the differentially expressed mRNAs in the biological process, cellular component and molecular function categories. The upregulated mRNAs were significantly enriched in a number of GO terms, with the two most prominent molecular function terms being ‘binding’ and ‘protein binding’ (GO:0005488 and GO:0005515; Fig. 3A), the most significant biological process term was ‘anatomical structure development’ (GO:0048856; Fig. 3A) and the most enriched cellular component was ‘non-membrane-bounded organelle’ (GO:0043228; Fig. 3A). The downregulated mRNAs were also significantly enriched in a number of GO terms, including ‘single-organism
process’ (GO:0044699) in biological processes and ‘cell part’ (GO:0044464) in cellular components (Fig. 3B). In addition, KEGG pathway analysis of the upregulated mRNAs indicated that the two most enriched pathways were ‘pathways in cancer’ and ‘PI3K-Akt signaling pathway’ (Fig. 4A), while the downregulated mRNAs were significantly involved in ‘valine, leucine and isoleucine degradation’ (Fig. 4B).

RT-qPCR validation. To validate the microarray data, RT-qPCR was conducted to detect the expression levels of six most significantly dysregulated lncRNAs (four upregulated and two downregulated) that were selected from the differentially expressed lncRNAs. These selected lncRNAs included ENSMUST00000140495, ENSMUST00000125649, AK006017, AK146794, ENSMUST00000120145 and AK089826. The PCR data were consistent with the microarray analysis results, with a concordance rate of 83.33% (5/6), supporting the reliability of the microarray data (Fig. 5A). Furthermore, as illustrated in Fig. 5B, RT-qPCR revealed that the expression levels of ENSMUST00000140495, ENSMUST00000125649, AK006017 and AK146794 were significantly increased in the tumor group compared with those in the control group, while AK089826 expression was significantly decreased. By contrast, there was no significant difference in the expression of ENSMUST00000120145 between the tumor and control groups (P>0.05; Fig. 5B).

Establishment of the lncRNA and mRNA co-expression network. Next, the study attempted to predict the target genes of lncRNAs and to investigate the potential interactions between the lncRNAs and mRNAs in PA in PLAG1 transgenic mice. The associations between the five validated lncRNAs and corresponding mRNAs were thus assessed by calculating the PCC values. The co-expression network was constructed and visualized using Cytoscape software based on the PCC value (PCC>0.99). The network illustrated a number of interactions between the five lncRNAs and a total of 725 mRNAs. The network also indicated that a single lncRNA may regulate the mRNA expression of multiple genes, and certain lncRNAs may co-regulate...
the expression of the same gene. For instance, AK146794 was able to regulate the expression of 264 mRNAs, while IGF2 was simultaneously regulated by ENSMUST00000140495 and ENSMUST00000125649 (Fig. 6).

**Discussion**

PA is the most common type of salivary gland tumor with a complex pathogenesis. PLAG1 transgenic mice have been utilized as a useful animal model to study PA. Although a number of genes (including PLAG1, HMGA2 and IGF2) have been proven to be involved in the pathogenesis of PA (7,21,22), it remains unclear how those genes are specifically regulated. With the rapid development of genomic technology, numerous non-coding RNAs (including microRNAs and lncRNAs) have been identified, and their roles in regulating mRNAs are currently researched.

In the present study, the lncRNA expression patterns in submandibular PA tissues of PLAG1 transgenic mice and normal tissues of wild-type C57BL/6 mice were compared using microarray analysis. The data demonstrated that a total of 9,110 lncRNAs were differentially expressed in the submandibular PA tissues obtained from PLAG1 transgenic mice when compared with their counterparts from the wild-type mice, which may facilitate the understanding of the PA-associated global transcriptome. In addition, it was observed that the differentially expressed lncRNAs and mRNAs in PA were distributed unequally among all chromosomes, including the X chromosome. Notably, all chromosomes were implicated in PA, providing additional evidence that the pathogenesis of PA is relatively complex.

Among the differentially expressed lncRNAs, intergenic lncRNAs comprised the largest category, with 1,850 upregulated and 2,163 downregulated members. Intergenic lncRNAs are conserved across multiple species and may function via various mechanisms, including transcriptional regulation, splicing regulation and post-transcriptional regulation (23). Furthermore, the majority of the validated lncRNAs in the present study belong to the category of intergenic lncRNAs, including ENSTMUST00000140495, AK006017, AK146794 ENSTMUST0000120145 and AK089826, which is consistent with the universality of intergenic lncRNAs.

To further understand the biological functions and molecular mechanisms of PA-associated mRNAs, GO and KEGG pathway analyses were also performed to identify the biological functions and signaling networks enriched among the differentially expressed mRNAs in the current study. Notably, these mRNAs were involved in multiple pathways associated with PA, including ‘PI3K-Akt signaling pathway’ and ‘p53 signaling pathway’. The PI3K-Akt signaling pathway, a key oncogenic pathway, has been reported to be overactivated in numerous tumors (24,25). The microarray results of the present study indicated that the expression of a number of key molecules of the PI3K-Akt pathway, including IRS1, PI3K, Ras and Akt, was increased. With regard to the p53 signaling pathway, it was observed that p21, Bax, Fas and CyclinD were also activated. However, with respect to intrinsic complex regulatory mechanisms, the specific role of these pathways in PA tumorigenesis warrants further investigation.

Unlike microRNAs, there are no reliable softwares that may be used to predict the target genes of lncRNAs and their functions via their sequence information or secondary
structure. Thus, the IncRNA-mRNA co-expression network has been developed to predict the potential roles of IncRNAs. In the present study, it was elucidated that the five validated IncRNAs may contribute to the development and progression of PA by altering the expression of target genes. Specifically, the IncRNA ENSMUST00000125649 was observed to be correlated with the IGF2, IGF2R and IGFBP5 mRNAs. In previous studies, it has been demonstrated that PLAG1 overexpression may be responsible for the frequent upregulation of IGF2.

Notably, thousands of dysregulated IncRNAs were identified in the current study, which is possibly due to the influence of PLAG1 overexpression in the transgenic mice. Future studies, particularly functional characterization of these IncRNAs, are thus required. Previous studies have demonstrated that IncRNAs have a wide range of biological functions mediated via various mechanisms, which include cis-targeting, trans-targeting and allosteric modification, and function as enhancers, scaffolds, and co-activators or co-repressors (23,27). A literature search conducted in the current study provided no research results on the aforementioned candidate IncRNAs, which suggests that further research is needed. Additionally, how these functional IncRNAs interact with the associated mRNAs in PA is another issue that merits further study, such as gain- and loss-of-function experiments in vivo, and tumor formation assays in vitro.

In conclusion, the present results demonstrated that a set of IncRNAs were differentially expressed in PA tissues obtained from PLAG1 transgenic mice. These IncRNAs may offer novel insights into the pathogenesis of PA and act as novel therapeutic targets for this tumor.

Acknowledgements

Not applicable.

Funding

This study was supported by the National Natural Science Foundation of China (grant no. 81302359) and the Research Grants from the Science and Technology Commission of Shanghai Municipality (grant no. 16ZR1418800).

Availability of data and materials

The datasets used and/or analyzed during the current study are available from the corresponding author on reasonable request.

Authors’ contributions

SS and WY conceived and designed the experiments. WX conducted RNA sequencing and analysis. LL and HL performed the experiments. WX and CZ wrote the manuscript. LL, JF and CZ conducted data analysis.

Ethics approval and consent to participate

All animal experiments were approved by The Ethics Committee of the Faculty of Medicine, Shanghai Jiao Tong University.

Patient consent for publication

Not applicable.

Competing interests

The authors declare that they have no competing of interests.

References

1. Li LJ, Li Y, Wen YM, Liu H and Zhao HW: Clinical analysis of salivary gland tumor cases in West China in past 50 years. Oral Oncol 44: 187-192, 2008.
2. Lima SS, Soares AF, Amorim RF and Freitas Rde A: Epidemiologic profile of salivary gland neoplasms: Analysis of 245 cases. Braz J Otorhinolaryngol 71: 335-340, 2005 (In Portuguese).
3. Tian Z, Li L, Wang L, Hu Y and Li J: Salivary gland neoplasms in oral and maxillofacial regions: A 23-year retrospective study of 6982 cases in an eastern Chinese population. Int J Oral Maxillofac Surg 39: 235-242, 2010.
4. Hu YH, Zhang CY, Xia RH, Tian Z, Wang LZ and Li J: Prognostic factors of carcinoma ex pleomorphic adenoma of the salivary glands, with emphasis on the widely invasive carcinoma: A clinicopathologic analysis of 361 cases in a Chinese population. Oral Surg Oral Med Oral Pathol Oral Radiol 122: 598-608, 2016.
5. Zatkova A, Rouillard JM, Hartmann W, Kuck R, Eckart M, von Schweinitz D, Koch A, Fonatsch C, Pietsch T et al: Amplification and overexpression of the IGF2 regulator PLAG1 in hepatoblastoma. Genes Chromosomes Cancer 39: 126-137, 2004.
6. Astrom A, D’Amore ES, Sainati L, Panarello C, Morerio C, Mark J and Stenman G: Evidence of involvement of the PLAG1 gene in lipoblastomas. Int J Oncol 16: 1107-1110, 2000.
7. Abi Habib W, Brioude F, Audran T, Bennett JT, Lienhardt-Roussie A, Tixier F, Salem J, Yuen T, Azzi S, Le Bouc Y, et al: Genetic disruption of the oncogenic HMGA2-PLAG1-IGF2 pathway causes fetal growth restriction. Genet Med 20: 250-258, 2018.
8. Juma AR, Grommen SVH, O’Bryan MK, O’Connor AE, Merrriner DJ, Hall NE, Doyle SR, Damdimopoulo PE, Barriga D, Hart AH, et al: PLAG1 deficiency impairs spermatogenesis and sperm motility in mice. Sci Rep 7: 5317, 2017.
9. Matsuyama A, Hisaoka M, Nagao Y and Hashimoto H: Aberrant PLAG1 expression in pleomorphic adenomas of the salivary gland: A molecular genetic and immunohistochemical study. Virchows Arch 458: 583-592, 2011.
10. Debiec-Rycerz M, Van Valckenborgh I, Van den Broeck C, Li LJ, Li Y, Wen YM, Liu H and Zhao HW: Clinical analysis of salivary gland tumor cases in West China in past 50 years. Oral Oncol 44: 187-192, 2008.
11. Avadhani V, Cohen C and Siddiqui MT: PLAG1: An immunohistochemical marker with limited utility in separating pleomorphic adenoma from other basaloid salivary gland tumors. Acta Cytol 60: 240-245, 2016.
12. Katabi N, Xu B, Jungbluth AA, Zhang L, Shao SY, Lane J, Ghossein R and Antonescu CR: PLAG1 immunohistochemistry is a sensitive marker for pleomorphic adenoma: A comparative study with PLAG1 genetic abnormalities. Histopathology 72: 285-293, 2018.
13. de Brito BS, Giovanelli N, Egal ES, Méndez-Ramirez C, Nascimento JS, Martins AS, Tincani AJ, Del Negro A, Gondak RO, Almeida OP, et al: Loss of expression of Plag1 in malignant transformation from pleomorphic adenoma to carcinoma ex pleomorphic adenoma. Hum Pathol 57: 152-159, 2016.
14. Zhao X, Ren W, Wang Y, Wang Y, Kong H, Wang L, Yan L, Xu G, Fei J, Fu J, et al: Wnt pathway is involved in pleomorphic adenomas induced by overexpression of PLAG1 in transgenic mice. Int J Cancer 118: 643-648, 2006.
15. Shen S, Wang Y, Wang Z, Lei X, Xu L, Wang Y, Wang L, Huang L, Yu Z, Zang X, et al: Tumor-initiating cells are enriched in CD44(hi) population in murine salivary gland tumor. PLoS One 6: e23282, 2011.
16. Wang Y, Shang W, Lei X, Shen S, Zhang H, Wang Z, Huang L, Yu Z, Ong H, Yin X, et al: Opposing functions of PLAG1 in pleomorphic adenoma: A microarray analysis of PLAG1 transgenic mice. Biotechnol Lett 35: 1377-1385, 2013.
17. Wang W, Wei C, Li P, Wang L, Li W, Chen K, Zhang J, Zhang W and Jiang G: Integrative analysis of mRNA and IncRNA profiles identified pathogenetic IncRNAs in esophageal squamous cell carcinoma. Gene 661: 169-175, 2018.
18. Li Y, Jin L, Dong A, Zhou X and Yuan H: Microarray expression profile analysis of long non-coding RNAs in optineurin E50K mutant transgenic mice. Mol Med Rep 16: 1255-1261, 2017.
19. Chen Z, Lin S, Li JL, Ni W, Guo R, Lu J, Kaye FJ and Wu L: MRTF1-MAML2 fusion-induced IncRNA LINC00473 expression maintains the growth and survival of human muco-epidermoid carcinoma cells. Oncogene 37: 1885-1895, 2018.
20. Shi H, Cao N, Pu Y, Xie L, Zheng L and Yu C: Long non-coding RNA expression profile in minor salivary gland of primary Sjögren's syndrome. Arthritis Res Ther 18: 109, 2016.
21. Declercq J, Van Dyck F, Van Damme B and Van de Ven WJ: Upregulation of Igf and Wnt signalling associated genes in pleomorphic adenomas of the salivary glands in PLAG1 transgenic mice. Int J Oncol 32: 1041-1047, 2008.
22. Voz ML, Agten NS, Van de Ven WJ and Kas K: PLAG1, the main translocation target in pleomorphic adenoma of the salivary glands, is a positive regulator of IGF-II. Cancer Res 60: 106-113, 2000.
23. Ponting CP, Oliver PL and Reik W: Evolution and functions of long noncoding RNAs. Cell 136: 629-641, 2009.
24. Fortin J and Mak TW: Targeting PI3K signaling in cancer: A cautionary tale of two AKTs. Cancer Cell 29: 429-431, 2016.
25. Wang X, Zhang X, Wang G, Wang L, Lin Y and Sun F: Hsa-miR-513b-5p suppresses cell proliferation and promotes P53 expression by targeting IRF2 in testicular embryonal carcinoma cells. Gene 626: 344-353, 2017.
26. Akhtar M, Holmgren C, Göndör A, Vesterlund M, Kanduri C, Larsson C and Ekström TJ: Cell type and context-specific function of PLAG1 for IGF2 P3 promoter activity. Int J Oncol 41: 1959-1966, 2012.
27. Ulitsky I and Bartel DP: lincRNAs: Genomics, evolution, and mechanisms. Cell 154: 26-46, 2013.

This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0) License.